Skip to main content

Vectormune HVT IBD (Canada)

This treatment applies to the following species:
Company: Ceva Animal Health

BURSAL DISEASE-MAREK’S DISEASE VACCINE

Serotype 3, Live Marek’s Disease Vector

See productdata.aphis.usda.gov for a summary of the studies approved by the USDA for licensing this product. The package insert may also contain additional information developed by the licensee.

Directions For Use

Description

VECTORMUNE® HVT IBD contains a genetically engineered Marek’s disease vaccine of serotype 3 (turkey herpesvirus or HVT) expressing an infectious bursal disease key protective antigen. This Marek’s disease vaccine containing serotype 3 is presented in a frozen cell associated form. The cells and virus particles are very fragile and require careful handling to prevent damage or loss of titer in order to achieve optimum efficacy. The vaccine is stored and shipped in frozen form in liquid nitrogen.

STORAGE CONDITIONS

● Vaccine ampules: Store in liquid nitrogen

● Diluent: Store at room temperature between 68-77°F (20-25°C)

Vectormune HVT IBD Indications

This product has been shown to be effective for the vaccination of healthy 18 to 19-day old embryonated eggs and healthy one day old chicks against bursal disease, due to Standard and Variant E viruses, and Marek’s Disease. The duration of immunity is unknown. For more information regarding efficacy and safety data, see productdata.aphis.usda.gov. Good management practices are recommended to reduce exposure to bursal disease virus and Marek’s disease virus for at least two weeks following vaccination.

Preparation And Administration Of Vaccine

Read the directions for use carefully. Instructions must be completely followed.

Match the vaccine dose size to the proper diluent size and route of administration as follows:

1. For subcutaneous injection of day-old chicks: Mix 200 mL of diluent for each 1,000 doses of vaccine.

One-day-old chicks are subcutaneously vaccinated with 0.2 mL of vaccine in the back of the neck.

2. For in ovo vaccination of 18 to 19 day-old chicken embryos: Mix 100 mL of diluent for each 1,000 doses of vaccine to administer 0.1 mL per chicken embryo or mix 50 mL for each 1,000 doses of vaccine to administer 0.05 mL per chicken embryo.

VACCINE PREPARATION

1. Be familiar with all safety and precautionary measures for handling liquid nitrogen to prevent personal injury.

2. Wear gloves, a plastic face shield and protective goggles before removing vaccine ampules from the liquid nitrogen.

3. Check the container to confirm a sufficient amount of liquid nitrogen is present to keep the vaccine frozen. If thawed, do not use the vaccine. The containers (Dewars) must be checked regularly for liquid nitrogen level and must be refilled as needed.

4. After matching the dose size of the vaccine with the diluent size, quickly remove the exact number of ampules needed.

5. A maximum of 3 ampules should be thawed at one time. After inspecting the diluent and completing all preparations, the vaccine should be quickly removed from the Dewar and placed into a clean 80°F (26.5°C) thaw bath. This step can be repeated until the appropriate dosage has been reached. Gentle agitation during the thawing process promotes rapid, uniform thawing and evenly distributes the vaccine in the ampule.

6. Immediately after thawing, mix the vaccine with the diluent at room temperature between 68-77°F (20-25°C). Gently draw the vaccine from the ampule with an 18-gauge, 1.5 inch needle and slowly mix with the diluent. Rinse the ampule one time with the diluted vaccine.

7. Immediately use the vaccine and mix occasionally to ensure uniform suspension of cells.

SUBCUTANEOUS VACCINATION

1. For subcutaneous injection, sterilize the automatic syringe, needles and other accessory equipment by autoclaving or boiling prior to vaccination.

2. Use a short (3/8 inch or 1/2 inch) 20-gauge needle for vaccination. Subcutaneously inject 0.2 mL into the back of the neck of each chick.

IN OVO VACCINATION

1. The vaccine is administered in ovo to 18 to 19 day-old embryonated eggs. Read the egg injection system operator’s manual before initiating vaccination. Failure to follow instructions may result in personal injury, excessive embryonic mortality and low hatchability. Inoculate each embryo with one full dose (0.05 mL or 0.1 mL).

2. Sanitize the egg injection system before and after use following the procedures described in the operator’s manual.

Notice

This vaccine has been thoroughly tested for safety, purity and potency and is in compliance with all applicable USDA and Ceva standards.

Vectormune HVT IBD Caution

1. Read the above directions carefully.

2. Do not vaccinate within 21 days before slaughter.

3. The vaccine contains gentamicin and amphotericin B as preservatives.

4. Inactivate unused contents before disposal.

5. Do not remove vaccine from liquid nitrogen until ready for use.

6. Do not refreeze the vaccine.

7. Use entire contents when first opened.

8. Do not use vaccine that has thawed in the liquid nitrogen container.

9. Do not overdose or over dilute the vaccine.

10. Do not mix with other products, except as specified on the label.

11. The effect of combining this vaccine with other products is not known and could impact vaccine efficacy.

12. In case of human exposure, contact a physician.

13. For use in animals only.

Ceva Animal Health, LLC Lenexa, KS 66215, U.S.A.

Phone: (913) 894-0230

VLN 368/PCN 1A88.R0

PX370XXUS-102

Presentation: 1,000 doses, 2,000 doses, and 4,000 doses.

CPN: 1221101.1

CEVA ANIMAL HEALTH INC.
150 RESEARCH LANE, SUITE 225, GUELPH, ON, N1G 4T2
Telephone:   519-650-9570
Toll-Free:   800-510-8864
Fax:   519-650-9576
Website:   www.ceva-canada.ca
Email:   service.canada@ceva.com
THIS SERVICE AND DATA ARE PROVIDED "AS IS". Animalytix assumes no liability, and each user assumes full risk, responsibility, and liability, related to its use of the Animalytix service and data. See the Terms of Use for further details.

Animalytix

Copyright © 2024 Animalytix LLC. Updated: 2024-02-27